{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:32:34Z","timestamp":1785414754747,"version":"3.56.0"},"reference-count":64,"publisher":"American Association for Cancer Research (AACR)","issue":"2","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by a poor prognosis owing to the lack of therapeutic targets, including hormone receptors and HER2. Systemic chemotherapy remains the primary treatment option; however, its efficacy is limited by chemotherapy resistance, a substantial challenge in clinical management. The present study aimed to develop a novel anticancer drug that overcomes chemotherapy resistance in TNBC. First, chemotherapy-resistant MDA-MB-468 cells derived from TNBC were developed via long-term exposure to adriamycin or paclitaxel. Compared with parental cells, these resistant cells exhibited reduced sensitivity to paclitaxel, adriamycin, and eribulin in the viability assays. Various compounds were screened for their cell growth\u2013inhibitory activity against these resistant cells to identify novel therapeutic agents; ZSTK3744 was a promising candidate and showed significant antitumor activity in vitro and in vivo. ZSTK3744 upregulated CYP1A1, CYP1B1, and TIPARP expression in MDA-MB-468 cells but exhibited no cell growth\u2013inhibitory activity in aryl hydrocarbon receptor (AhR)\u2013knockout cells, indicating that ZSTK3744 acts as an AhR agonist. Notably, ZSTK3744 demonstrated superior tumor inhibition and lower pulmonary toxicity in ex vivo and in vivo models than other AhR agonists. These results suggest that ZSTK3744 combines robust cell growth\u2013inhibitory activity with a favorable safety profile. In conclusion, ZSTK3744 is a promising candidate for overcoming chemotherapy resistance in TNBC, addressing the urgent need for more effective treatment options for this aggressive cancer subtype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>ZSTK3744 was identified through screening for its cell growth\u2013inhibitory activity on chemotherapy-resistant TNBC cells. ZSTK3744 exerts its activity through AhR. ZSTK3744 exhibits superior cell growth\u2013inhibitory activity compared with other AhR agonists and demonstrates a favorable safety profile. Therefore, ZSTK3744 is a promising therapeutic agent for overcoming chemotherapy resistance in TNBC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0119","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T18:20:36Z","timestamp":1770056436000},"page":"421-436","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4669-3119","authenticated-orcid":false,"given":"Takahiro","family":"Ohashi","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00vx6je85","id-type":"ROR","asserted-by":"publisher"}],"name":"Zenyaku Kogyo Co., Ltd. 1 Biosciences, Department of Drug Discovery, R&D Center, , Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8098-1508","authenticated-orcid":false,"given":"Tsubasa","family":"Nagasaki","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00vx6je85","id-type":"ROR","asserted-by":"publisher"}],"name":"Zenyaku Kogyo Co., Ltd. 2 Organic Synthesis, Department of Drug Discovery, R&D Center, , Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1245-711X","authenticated-orcid":false,"given":"Kayoko","family":"Kawai-Asami","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00vx6je85","id-type":"ROR","asserted-by":"publisher"}],"name":"Zenyaku Kogyo Co., Ltd. 3 Pharmacology, Department of Drug Discovery, R&D Center, , Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8606-3018","authenticated-orcid":false,"given":"Kotomi","family":"Akatsuka","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00vx6je85","id-type":"ROR","asserted-by":"publisher"}],"name":"Zenyaku Kogyo Co., Ltd. 1 Biosciences, Department of Drug Discovery, R&D Center, , Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6676-5661","authenticated-orcid":false,"given":"Yuko","family":"Nagata","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00vx6je85","id-type":"ROR","asserted-by":"publisher"}],"name":"Zenyaku Kogyo Co., Ltd. 3 Pharmacology, Department of Drug Discovery, R&D Center, , Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3493-5530","authenticated-orcid":false,"given":"Sayuri","family":"Terada","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00vx6je85","id-type":"ROR","asserted-by":"publisher"}],"name":"Zenyaku Kogyo Co., Ltd. 1 Biosciences, Department of Drug Discovery, R&D Center, , Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2321-242X","authenticated-orcid":false,"given":"Shinsuke","family":"Hiramoto","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00vx6je85","id-type":"ROR","asserted-by":"publisher"}],"name":"Zenyaku Kogyo Co., Ltd. 1 Biosciences, Department of Drug Discovery, R&D Center, , Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2093-8074","authenticated-orcid":false,"given":"Eika","family":"Higashi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00vx6je85","id-type":"ROR","asserted-by":"publisher"}],"name":"Zenyaku Kogyo Co., Ltd. 2 Organic Synthesis, Department of Drug Discovery, R&D Center, , Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9174-6915","authenticated-orcid":false,"given":"Ryuichiro","family":"Ohshita","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00vx6je85","id-type":"ROR","asserted-by":"publisher"}],"name":"Zenyaku Kogyo Co., Ltd. 2 Organic Synthesis, Department of Drug Discovery, R&D Center, , Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5669-0691","authenticated-orcid":false,"given":"Mizuki","family":"Kuramochi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00vx6je85","id-type":"ROR","asserted-by":"publisher"}],"name":"Zenyaku Kogyo Co., Ltd. 4 Safety Evaluation, Department of Drug Discovery, R&D Center, , Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8252-3954","authenticated-orcid":false,"given":"Makoto","family":"Furuya","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00vx6je85","id-type":"ROR","asserted-by":"publisher"}],"name":"Zenyaku Kogyo Co., Ltd. 4 Safety Evaluation, Department of Drug Discovery, R&D Center, , Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9584-5275","authenticated-orcid":false,"given":"Mai","family":"Todoroki","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00vx6je85","id-type":"ROR","asserted-by":"publisher"}],"name":"Zenyaku Kogyo Co., Ltd. 4 Safety Evaluation, Department of Drug Discovery, R&D Center, , Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4740-0164","authenticated-orcid":false,"given":"Hisashi","family":"Yoshimi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00vx6je85","id-type":"ROR","asserted-by":"publisher"}],"name":"Zenyaku Kogyo Co., Ltd. 4 Safety Evaluation, Department of Drug Discovery, R&D Center, , Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2518-4870","authenticated-orcid":false,"given":"Keiko","family":"Fukushima","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00vx6je85","id-type":"ROR","asserted-by":"publisher"}],"name":"Zenyaku Kogyo Co., Ltd. 1 Biosciences, Department of Drug Discovery, R&D Center, , Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"2026050611213183800_bib1","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"2026050611213183800_bib2","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1158\/1078-0432.CCR-13-0799","article-title":"Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes","volume":"19","author":"Masuda","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2026050611213183800_bib3","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3390\/pharmaceutics15071796","article-title":"Triple negative breast cancer treatment options and limitations: future outlook","volume":"15","author":"Obidiro","year":"2023","journal-title":"Pharmaceutics"},{"key":"2026050611213183800_bib4","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ajpath.2013.05.033","article-title":"Triple-negative breast cancer and the need for new therapeutic targets","volume":"183","author":"Engebraaten","year":"2013","journal-title":"Am J Pathol"},{"key":"2026050611213183800_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2026050611213183800_bib6","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1158\/2159-8290.CD-13-0286","article-title":"Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets","volume":"4","author":"Balko","year":"2014","journal-title":"Cancer Discov"},{"key":"2026050611213183800_bib7","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1200\/JCO.22.02572","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"41","author":"Liedtke","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026050611213183800_bib8","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026050611213183800_bib9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10549-021-06193-9","article-title":"Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer","volume":"188","author":"Ahn","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"2026050611213183800_bib10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.5603\/OCP.2022.0003","article-title":"Sacituzumab govitecan \u2014 a new therapy for patients with triple-negative breast cancer","volume":"19","author":"Pogoda","year":"2023","journal-title":"Oncol Clin Pract"},{"key":"2026050611213183800_bib11","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s12282-019-01043-5","article-title":"Microsatellite instability in Japanese female patients with triple-negative breast cancer","volume":"27","author":"Kurata","year":"2020","journal-title":"Breast Cancer"},{"key":"2026050611213183800_bib12","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10549-014-2980-0","article-title":"Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and\/or ovarian cancer syndrome testing","volume":"145","author":"Sharma","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"2026050611213183800_bib13","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10549-016-3792-1","article-title":"Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial","volume":"156","author":"Gonz\u00e1lez-Rivera","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"2026050611213183800_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13058-024-01783-z","article-title":"HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: are they connected?","volume":"26","author":"Baez-Navarro","year":"2024","journal-title":"Breast Cancer Res"},{"key":"2026050611213183800_bib15","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.clbc.2023.05.015","article-title":"The effect of HER2-low status on pathological complete response and survival in triple-negative breast cancer: a systematic review and meta-analysis","volume":"23","author":"Ergun","year":"2023","journal-title":"Clin Breast Cancer"},{"key":"2026050611213183800_bib16","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3390\/cells8090957","article-title":"Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge","volume":"8","author":"Nedeljkovi\u0107","year":"2019","journal-title":"Cells"},{"key":"2026050611213183800_bib17","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.3390\/ijms23031665","article-title":"Molecular mechanisms, biomarkers and emerging therapies for chemotherapy resistant TNBC","volume":"23","author":"Ferrari","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026050611213183800_bib18","doi-asserted-by":"crossref","first-page":"BSR20204092","DOI":"10.1042\/BSR20204092","article-title":"Role of ABCB1 in mediating chemoresistance of triple-negative breast cancers","volume":"41","author":"Abd El-Aziz","year":"2021","journal-title":"Biosci Rep"},{"key":"2026050611213183800_bib19","doi-asserted-by":"crossref","first-page":"114542","DOI":"10.1016\/j.ejmech.2022.114542","article-title":"Cancer multidrug-resistance reversal by ABCB1 inhibition: a recent update","volume":"239","author":"Engle","year":"2022","journal-title":"Eur J Med Chem"},{"key":"2026050611213183800_bib20","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.3390\/ijms22063199","article-title":"Pleiotropic roles of ABC transporters in breast cancer","volume":"22","author":"He","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026050611213183800_bib21","doi-asserted-by":"crossref","first-page":"70011","DOI":"10.18632\/oncotarget.11727","article-title":"ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines","volume":"7","author":"Oba","year":"2016","journal-title":"Oncotarget"},{"key":"2026050611213183800_bib22","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/bjc.2016.203","article-title":"ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells","volume":"115","author":"Vaidyanathan","year":"2016","journal-title":"Br J Cancer"},{"key":"2026050611213183800_bib23","doi-asserted-by":"crossref","first-page":"398","DOI":"10.2174\/156800909788166529","article-title":"Breast cancer: understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicine","volume":"9","author":"Germano","year":"2009","journal-title":"Curr Cancer Drug Targets"},{"key":"2026050611213183800_bib24","doi-asserted-by":"crossref","first-page":"e62766","DOI":"10.1371\/journal.pone.0062766","article-title":"Neoadjuvant chemotherapy induces expression levels of breast cancer resistance protein that predict disease-free survival in breast cancer","volume":"8","author":"Kim","year":"2013","journal-title":"PLoS One"},{"key":"2026050611213183800_bib25","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s10549-012-2398-5","article-title":"High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival","volume":"137","author":"Yamada","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"2026050611213183800_bib26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.immuni.2017.12.012","article-title":"Regulation of the immune response by the aryl hydrocarbon receptor","volume":"48","author":"Guti\u00e9rrez-V\u00e1zquez","year":"2018","journal-title":"Immunity"},{"key":"2026050611213183800_bib27","doi-asserted-by":"crossref","first-page":"168296","DOI":"10.1016\/j.jmb.2023.168296","article-title":"The AhR signaling mechanism: a structural point of view","volume":"436","author":"Bonati","year":"2024","journal-title":"J Mol Biol"},{"key":"2026050611213183800_bib28","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s12016-020-08789-3","article-title":"The aryl hydrocarbon receptor (AHR) as a potential target for the control of intestinal inflammation: insights from an immune and bacteria sensor receptor","volume":"59","author":"Pernomian","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026050611213183800_bib29","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s12276-023-01028-7","article-title":"Immune regulation through tryptophan metabolism","volume":"55","author":"Seo","year":"2023","journal-title":"Exp Mol Med"},{"key":"2026050611213183800_bib30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13578-023-01046-y","article-title":"Modulating AHR function offers exciting therapeutic potential in gut immunity and inflammation","volume":"13","author":"Chen","year":"2023","journal-title":"Cell Biosci"},{"key":"2026050611213183800_bib31","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.3390\/ijms25084527","article-title":"Aryl hydrocarbon receptor signalling in the control of gut inflammation","volume":"25","author":"Marafini","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026050611213183800_bib32","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1007\/s00204-017-1981-2","article-title":"Role of the aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target","volume":"91","author":"Kolluri","year":"2017","journal-title":"Arch Toxicol"},{"key":"2026050611213183800_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2023.12.013","article-title":"Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: a clinical review","volume":"154","author":"Silverberg","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"2026050611213183800_bib34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cotox.2017.01.012","article-title":"The Aryl Hydrocarbon Receptor (AhR) as a drug target for cancer chemotherapy","volume":"2","author":"Safe","year":"2017","journal-title":"Curr Opin Toxicol"},{"key":"2026050611213183800_bib35","doi-asserted-by":"crossref","first-page":"e0190619","DOI":"10.1371\/journal.pone.0190619","article-title":"High AHR expression in breast tumors correlates with expression of genes from several signaling pathways namely inflammation and endogenous tryptophan metabolism","volume":"13","author":"Vacher","year":"2018","journal-title":"PLoS One"},{"key":"2026050611213183800_bib36","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3390\/ijms22020752","article-title":"AhR and cancer: from gene profiling to targeted therapy","volume":"22","author":"Paris","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026050611213183800_bib37","doi-asserted-by":"crossref","first-page":"e007495","DOI":"10.1136\/jitc-2023-007495","article-title":"Targeting the aryl hydrocarbon receptor (AhR) with BAY2416964: a selective small molecule inhibitor for cancer immunotherapy","volume":"11","author":"Kober","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026050611213183800_bib38","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.3390\/ijms21103551","article-title":"New treatments in renal cancer: the AhR ligands","volume":"21","author":"Itkin","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026050611213183800_bib39","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1158\/1535-7163.715.3.6","article-title":"Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells","volume":"3","author":"Loaiza-P\u00e9rez","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"2026050611213183800_bib40","doi-asserted-by":"crossref","first-page":"9656","DOI":"10.1158\/0008-5472.CAN-06-0796","article-title":"Activation of aminoflavone (NSC 686288) by a sulfotransferase is required for the antiproliferative effect of the drug and for induction of histone gamma-H2AX","volume":"66","author":"Meng","year":"2006","journal-title":"Cancer Res"},{"key":"2026050611213183800_bib41","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/sj.bjc.6600722","article-title":"DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F-203, NSC703786) is attenuated in aryl hydrocarbon receptor-deficient MCF-7 cells","volume":"88","author":"Trapani","year":"2003","journal-title":"Br J Cancer"},{"key":"2026050611213183800_bib42","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/med.21645","article-title":"The aryl hydrocarbon receptor (AhR) as a breast cancer drug target","volume":"40","author":"Baker","year":"2020","journal-title":"Med Res Rev"},{"key":"2026050611213183800_bib43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3892\/mmr.2023.13134","article-title":"Aryl hydrocarbon receptor: an emerging player in breast cancer pathogenesis and its potential as a drug target (Review)","volume":"29","author":"Chen","year":"2024","journal-title":"Mol Med Rep"},{"key":"2026050611213183800_bib44","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1021\/acsptsci.2c00253","article-title":"Induction of aryl hydrocarbon receptor-mediated cancer cell-selective apoptosis in triple-negative breast cancer cells by a high-affinity benzimidazoisoquinoline","volume":"6","author":"Elson","year":"2023","journal-title":"ACS Pharmacol Transl Sci"},{"key":"2026050611213183800_bib45","doi-asserted-by":"crossref","first-page":"6004","DOI":"10.1002\/jcb.27887","article-title":"Putative tumor suppressor cytoglobin promotes aryl hydrocarbon receptor ligand-mediated triple negative breast cancer cell death","volume":"120","author":"Rowland","year":"2019","journal-title":"J Cell Biochem"},{"issue":"Suppl 15","key":"2026050611213183800_bib46","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/jco.2011.29.15_suppl.2546","article-title":"A phase I study of once-weekly aminoflavone prodrug (AFP464) in solid tumor patients","volume":"29","author":"Goetz","year":"2011","journal-title":"J Clin Oncol"},{"key":"2026050611213183800_bib47","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3390\/biomedicines9030290","article-title":"Intratumoural cytochrome P450 expression in breast cancer: impact on standard of care treatment and new efforts to develop tumour-selective therapies","volume":"9","author":"Sneha","year":"2021","journal-title":"Biomedicines"},{"key":"2026050611213183800_bib48","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/toxsci\/kfs319","article-title":"In vitro exposure of precision-cut lung slices to 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole lysylamide dihydrochloride (NSC 710305, Phortress) increases inflammatory cytokine content and tissue damage","volume":"131","author":"Behrsing","year":"2013","journal-title":"Toxicol Sci"},{"key":"2026050611213183800_bib49","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13058-019-1150-z","article-title":"Nicotinamide N-methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization","volume":"21","author":"Wang","year":"2019","journal-title":"Breast Cancer Res"},{"key":"2026050611213183800_bib50","doi-asserted-by":"crossref","first-page":"1116061","DOI":"10.3389\/fonc.2023.1116061","article-title":"The dual role of p63 in cancer","volume":"13","author":"Xu","year":"2023","journal-title":"Front Oncol"},{"key":"2026050611213183800_bib51","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/jnci\/djj133","article-title":"Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor","volume":"98","author":"Yaguchi","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"2026050611213183800_bib52","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1111\/cas.12004","article-title":"Establishment of phosphatidylinositol 3-kinase inhibitor-resistant cancer cell lines and therapeutic strategies for overcoming the resistance","volume":"103","author":"Isoyama","year":"2012","journal-title":"Cancer Sci"},{"key":"2026050611213183800_bib53","doi-asserted-by":"crossref","first-page":"e002279","DOI":"10.1136\/jitc-2020-002279","article-title":"Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal","volume":"9","author":"Isoyama","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026050611213183800_bib54","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/ijc.23244","article-title":"Aminoflavone induces oxidative DNA damage and reactive oxidative species-mediated apoptosis in breast cancer cells","volume":"122","author":"McLean","year":"2008","journal-title":"Int J Cancer"},{"key":"2026050611213183800_bib55","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1021\/tx500485v","article-title":"Aryl hydrocarbon receptor ligand 5F 203 induces oxidative stress that triggers DNA damage in human breast cancer cells","volume":"28","author":"McLean","year":"2015","journal-title":"Chem Res Toxicol"},{"key":"2026050611213183800_bib56","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.tiv.2016.01.006","article-title":"Prevalidation of the ex-vivo model PCLS for prediction of respiratory toxicity","volume":"32","author":"Hess","year":"2016","journal-title":"Toxicol In Vitro"},{"key":"2026050611213183800_bib57","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.18632\/aging.101010","article-title":"Lymphoid malignancies ARNT unstoppable","volume":"8","author":"Gardella","year":"2016","journal-title":"Aging (Albany, NY)"},{"key":"2026050611213183800_bib58","doi-asserted-by":"crossref","first-page":"e2114336119","DOI":"10.1073\/pnas.2114336119","article-title":"AhR promotes phosphorylation of ARNT isoform 1 in human T cell malignancies as a switch for optimal AhR activity","volume":"119","author":"Bourner","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026050611213183800_bib59","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.3390\/ijms19123882","article-title":"The aryl hydrocarbon receptor and the maintenance of lung health","volume":"19","author":"Guerrina","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2026050611213183800_bib60","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1038\/s44321-024-00135-w","article-title":"The influence of AHR on immune and tissue biology","volume":"16","author":"Stockinger","year":"2024","journal-title":"EMBO Mol Med"},{"key":"2026050611213183800_bib61","volume-title":"Supporting the discovery and development of novel cancer diagnostics and therapeutics","author":"Division of Cancer Treatment and Diagnosis, National Cancer Institute"},{"key":"2026050611213183800_bib62","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.3390\/cancers14225574","article-title":"The role of the aryl hydrocarbon receptor (AhR) and its ligands in breast cancer","volume":"14","author":"Safe","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026050611213183800_bib63","doi-asserted-by":"crossref","first-page":"6654","DOI":"10.3390\/ijms21186654","article-title":"Aryl hydrocarbon receptor (AhR) ligands as selective AhR modulators (SAhRMs)","volume":"21","author":"Safe","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026050611213183800_bib64","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1124\/mol.109.061788","article-title":"Development of a selective modulator of aryl hydrocarbon receptor","volume":"77","author":"Murray","year":"2010","journal-title":"Mol Pharmacol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0119\/3732363\/crc-25-0119.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/2\/421\/3743448\/crc-25-0119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/2\/421\/3743448\/crc-25-0119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:21:43Z","timestamp":1778080903000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/2\/421\/774901\/ZSTK3744-a-Novel-Aryl-Hydrocarbon-Receptor-Agonist"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0119","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.32699920","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699899","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429914","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429916","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429938","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429928","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429932","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429910","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429944","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429922","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429956","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429934","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699926","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429924","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699914","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429950","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429940","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429962","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429920","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699911","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699896","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699917","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429959","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699905","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699923","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31429953","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8329370","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,1]]}}}